Treating Auto-inflammatory Diseases with Interleukin-1 beta Blockade
Date & Time:
Dr. Charles Dinarello, who purified and cloned interleukin-1beta (IL 1beta), once known as the fever molecule, will deliver the 2010 Kinyoun Lecture on Thursday, Nov. 18, at 3 p.m. in Lipsett Amphitheater, Bldg. 10. Dinarello is professor of medicine and immunology at the University of Colorado School of Medicine and a former investigator in NIAID’s Laboratory of Clinical Investigation.
Dinarello’s talk, titled “Treating Auto-inflammatory Diseases with Interleukin-1 beta Blockade,” will include an overview of autoinflammatory diseases, such as type 2 diabetes mellitus and gout, and describe differences between these and autoimmune diseases. He also will discuss treatment of inflammatory diseases using IL-1beta blocking agents.
Considered one of the founding fathers of cytokine biology, Dinarello’s work with IL-1 helped to establish the significance of cytokines in inflammatory diseases. His recognition of the importance of IL-1 in inflammatory diseases led to the development of therapies that inhibit IL-1 and thereby reduce disease severity. These therapies include those based on the IL-1 receptor antagonist, monoclonal antibodies and soluble receptors.